Sex-specific risk loci and modified MEF2C expression in ALS

Ross P Byrne^{1*}, Wouter van Rheenen², Tomás DS Gomes¹, Ciarán M Kelly³, Emrah Kaçar¹, Project MinE ALS GWAS Consortium⁴, International ALS/FTD Genomics Consortium⁵, Ahmad Al Khleifat^{6,7}, Alfredo Iacoangeli^{6,7,8,9}, Ammar Al-Chalabi^{6,10}, Jan H Veldink², Russell L McLaughlin¹

* To whom correspondence should be addressed:

Ross P Byrne PhD
Complex Trait Genomics Laboratory
Smurfit Institute of Genetics
Trinity College Dublin
D02 PN40, Republic of Ireland

 Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, D02 PN40, Ireland

Email: rbyrne5@tcd.ie

- 2 Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands
- 3 School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
- 4 A full list of authors and their affiliations appears in Supplementary note 1
- 5 A full list of authors and their affiliations appears in Supplementary note 2
- 6 King's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London SE5 9RX, United Kingdom
- 7 Perron Institute for Neurological and Translational Science, University of Western Australia Medical School, Perth, WA 6009, Australia
- 8 Department of Biostatistics and Health Informatics, King's College London, London, United Kingdom
- 9 NIHR BRC SLAM NHS Foundation Trust, London, United Kingdom
- 10 King's College Hospital, Denmark Hill, SE5 9RS London, UK.

Significantly more men develop amyotrophic lateral sclerosis (ALS) than women, and heritability is not uniform between male and female transmissions, together suggesting a role for sex in the genetic aetiology of the disease. We therefore performed sex-stratified genome-wide and transcriptome-wide analyses of ALS risk, identifying six novel sex-specific risk loci including *MEF2C*, which shows increased expression in female ALS motor neurones. X-chromosome analysis revealed an additional risk locus at *IL1RAPL2*.

- 6 We calculated that previously-reported¹ differences in like-sexed and unlike-sexed parent-offspring transmission
- ⁷ concordance for ALS implies a female-male genetic correlation of 62.8% (95% c.i. 48.0-73.2%), suggesting that some
- 8 inherited ALS risk factors differ between women and men. To investigate this, we re-analysed the largest genome-
- 9 wide association study (GWAS) of ALS², splitting autosomal data by sex ($n_{\text{female}} = 67,957$; $n_{\text{male}} = 65,692$;
- 10 Supplementary table 1), which revealed novel female-specific risk loci at *FGFRL1* and *MEF2C* and male-specific risk
- 11 Inoiret Childrephint, Report how Weledren under has the generative of the supplementary not be the the two uncertained primplicated



Figure 1 Sex-stratified genome-wide association study (GWAS) statistics for amyotrophic lateral sclerosis (ALS) risk, including sex-combined X-chromosome association statistics. For sex-stratified analyses, the p-value threshold to consider a locus as significantly associated with ALS corresponds to a false discovery rate of 1%. Combined X chromosome analysis uses the conventional genome-wide significance threshold of 5×10^{-8} . Significant loci are annotated with their closest gene and for brevity, only loci where p < 0.001 are plotted. For the six novel sex-specific loci (underlined), cohort- and locus-level detail are provided in Supplementary figure 2-7.

loci (HLA locus and SCFD1) were only significantly associated with ALS risk in males, but did not meet our definition 12 of sex-specific ($p < 2.3 \times 10^{-7}$ in one sex, corresponding to a false discovery rate < 1%, and p > 0.05 in the other sex). 13 GWAS statistics for both sexes were modestly inflated ($\lambda_{GC} = 1.03$ in both; Supplementary figure 1) suggesting some 14 polygenic risk, which was further supported by univariate LD score regression³ heritability estimates (h_{SNP}^2 (s.e.) = 15 2.8% (0.65) for females and 2.1% (0.42) for males), with no apparent role for confounding in GWAS inflation (LDSC 16 intercepts < 1). Despite the identification of sex-specific loci, bivariate LD score regression⁴ estimated the genetic 17 correlation between male and female autosomal GWAS statistics to be 99% (s.e. 16%; p=4.1×10⁻¹⁰), suggesting an 18 overall shared polygenic component of ALS risk architecture between the two sexes. X chromosome data were 19 available for a subset of individuals ($n_{\text{female}} = 19,576$; $n_{\text{male}} = 21,991$); these were analysed per sex then resulting 20 statistics were meta-analysed, revealing one further novel ALS-associated risk locus at IL1RAPL2 (Figure 1 21 Supplementary table 3). 22

To identify gene expression modified by ALS risk alleles, we performed a transcriptome-wide association study 23 (TWAS) of sex-stratified GWAS results with expression data for 13 brain tissues in GTEx version 8. A previously-24 noted⁵ association between ALS risk and expression of *C9orf72* was observed in both sexes and modified expression 25 of MEF2C and RESP18 were associated with ALS risk in a strongly sex-specific manner (Figure 2A, Supplementary 26 table 4). Of the other GWAS risk loci, only SCFD1 was significantly associated by TWAS analysis in males, but this 27 was not sex-specific ($p_{\text{female}} = 1.81 \times 10^{-5}$). Notably, independent analysis of motor neurones (MNs) derived from 28 induced pluripotent stem cells (IPSCs) from ALS patients and controls⁶ revealed MEF2C expression to be significantly 29 higher in female ALS patients than in female controls ($p_{\text{female}} = 3 \times 10^{-4}$, Figure 2B), but not significantly different 30 between male ALS patients and male controls ($p_{male} = 0.07$). 31

MEF2C is a transcription factor involved in development of the mammalian neocortex, and has been associated with 32 Alzheimer's and Parkinson's diseases, along with several neuropsychiatric traits. As ALS risk modulated by MEF2C 33 expression likely involves its transcriptional targets, we reasoned that genetic variation present in target genes may 34 also confer risk for ALS. We therefore performed stratified LD score regression⁷ to identify partitioned heritability 35 enrichment for ALS in a set of 1,055 genes either up- or downregulated in Mef2c conditional knockout mice^{8,9}, 36 revealing 2.4-fold heritability enrichment in human orthologues of downregulated genes in female ALS GWAS 37 statistics ($p = 2.6 \times 10^{-3}$) and a statistically insignificant heritability depletion in upregulated targets (p = 0.56). No 38 significant heritability enrichment was observed in male ALS GWAS statistics (Supplementary table 5). 39



Figure 2 Sex-specific analysis of gene expression in amyotrophic lateral sclerosis (ALS). (A) Transcriptome-wide association study (TWAS) statistics using GWAS results from Figure 1 analysed with expression data from 13 brain tissues in GTEx version 8. Significance threshold is Bonferroni-corrected for 14,706 tests. Genes whose expression are significantly modified by ALS GWAS risk alleles are annotated and for brevity, only loci where p < 0.1 are plotted. (B) For TWAS loci identified as sex-specific ($p < 3.4 \times 10^{-6}$ in one sex; p > 0.05 in the other), boxplots show sex-stratified expression (counts per million, CPM) in an independent set of motor neurones (MNs) derived from induced pluripotent stem cells (IPSCs) generated from 471 ALS patients and 283 age-matched controls in Answer ALS⁶. * $p < 8.3 \times 10^{-3}$ (logistic regression, corrected for 6 tests).

It is possible that MEF2C transcriptomic results partially explain the sex ratio in ALS¹⁰: although dysregulation of 40 MEF2C targets has previously been implicated in ALS in sex-agnostic analyses¹¹, our data suggest that lower 41 expression in female motor neurones is protective against ALS, and increased expression to the range observed in 42 men (who are generally at higher risk) increases risk in women. It is also worth noting that the IPSC MN system is 43 isolated from endocrine differences between men and women, so sex differences are likely due to cell-autonomous 44 regulation or sex-divergent epigenetic cellular identity established over the lifetime of the individual. This contrasts 45 with *RESP18*, whose expression in MNs was not significantly different between cases and controls of either sex, 46 despite its association by TWAS in men. As RESP18 encodes a secreted neuroendocrine protein, it is not necessarily 47 expected that IPSC MN expression in isolation would differ between ALS cases and controls. However, MN 48 expression was lower in men overall than in women ($p = 1.09 \times 10^{-9}$), and female rats have previously been shown to 49 express twice the level of RESP18 protein in plasma compared to male rats¹², consistent with a possible role for sex 50 in determining its contribution to neurodegeneration. In support of this, Resp18 knockout impairs locomotor activity 51 and motor coordination but appears to protect against behavioural impairment in a chemically-induced model of 52 Parkinson's disease in male mice¹³. 53

Although gene expression changes at remaining novel autosomal GWAS loci (CCDC85A, FGFRL1, WIPI2 and 54 LUZP2) were not significantly associated with ALS by TWAS, these genes also have biological roles that may 55 contribute to candidate disease mechanisms in ALS when their risk alleles are inherited. CCDC85A is highly expressed 56 in the frontal cortex, associating with synaptic function and interactions between neurones and astrocytes. The 57 FGFRL1 locus also includes IDUA, which has been associated with Alzheimer's disease¹⁴, and GAK, which was 58 previously associated with Parkinson's disease¹⁵ and implicated as a shared risk locus through colocalization analysis 59 in sex-agnostic ALS GWAS². WIPI2 is involved in autophagy (a key process in ALS pathophysiology), and interacts 60 61 with ALS-related proteins TBK1 and optineurin. LUZP2 has recently been associated with age at onset of Alzheimer's disease¹⁶. Finally, *IL1RAPL2* was revealed by X chromosome analysis, which has previously been overlooked in ALS 62 genomics. This encodes a central nervous system-specific protein which is part of the interactome of interleukin-2, a 63 cytokine currently under clinical trial investigating its potential neuroprotective effect in ALS¹⁷. Stratification of trial 64 results by rs17332232 genotype may reveal a pharmacogenomic element to any observed therapeutic benefit. 65

66 Methods

67 Pedigree-based genetic correlation estimation

Heritability estimates from like-sexed (mother-daughter and father-son) and unlike-sexed (mother-son and fatherdaughter) parent-offspring pairings were obtained from Ryan et al $(2019)^1$ to estimate genetic correlation in ALS

⁷⁰ liability between sexes. Falconer (1967)¹⁸ expresses this as

$$r_{\rm g} = \frac{h_{\rm female}h_{male} \ (unlike - sexed)}{h_{\rm female}h_{\rm male} \ (like - sexed)},$$

where $r_{\rm g}$ is the genetic correlation between sexes and $h_{\rm female}$ and $h_{\rm male}$ are the square roots of heritability in female and male cohorts, respectively. Confidence intervals were calculated using the upper and lower bounds of the 95% confidence intervals from the source study in the numerator and denominator, respectively for the upper bound, and *vice versa* for the lower bound.

⁷⁶ Sex-stratified genome-wide association study

Genotype data were obtained from the European component the ALS GWAS presented by van Rheenen et al. (2021)². 77 Only variants and individuals passing quality control (QC) described in the original publication were retained for 78 analysis. The source study subdivides data into six strata representing similar genotyping platforms; these same strata 79 were used and further subdivided into male-only and female-only subsets based on reported sex (Supplementary table 80 1). One sample from any pair with a coefficient of relatedness greater than 0.125 (calculated over 150k SNPs) between 81 the male and female subsets of each stratum was removed to avoid potential bias in analyses comparing the two sex-82 specific GWAS subsets (e.g. genetic correlation analysis). Samples with relatedness within each stratum were 83 retained; these are appropriately handled by SAIGE v0.3919, which we used to calculate association statistics per 84 stratum. Firstly, we fit a null logistic mixed model in a leave-one chromosome out scheme per stratum using the first 85 20 principal components as covariates. For this model we used a subset of high-quality (INFO > 0.95) SNPs which 86 were LD pruned using PLINK 1.9 (--indep-pairwise 50 25 0.05 and high LD regions removed: 87 https://genome.sph.umich.edu/wiki/Regions of high linkage disequilibrium (LD)). Next we ran a SNP-wise 88 logistic mixed model implementing a saddlepoint approximation on all hard called genotypes in a leave one 89 chromosome out scheme. Resulting sex-specific association statistics were combined across strata using inverse 90 variance weighted meta-analysis implemented in METAL²⁰. Associated loci were classified as sex-specific if 91 significantly associated with ALS in one sex after stringent correction for multiple testing (1% false discovery rate; 92 Benjamini-Hochberg) but not even nominally associated in the other sex (p > 0.05). 93

⁹⁴ To estimate SNP-based heritability we ran univariate LD score regression on sex-specific GWAS summary statistics,

using pre-calculated LD scores from the European subsample of the 1000 Genomes Project and considering only SNPs

⁹⁶ included in HapMap phase 3. Heritability estimates were converted to the liability scale using sex-specific lifetime

- ⁹⁷ risk estimates for ALS¹ (1 in 436 for women; 1 in 347 for men) as prevalence. The sum of effective sample sizes (i.e.
- the effective sample size of an equivalent GWAS with a 50:50 case control split) was used in place of total N, and
- sample prevalence was set at 0.5 following evidence that using total N and sample prevalence downwardly biases

heritability estimates when GWAS results from meta-analysis of several cohorts with different ascertainment²¹.

Effective sample size was calculated as $\frac{4N_{ALS}N_{control}}{N_{ALS}+N_{control}}$ in each stratum and summed across strata.

102 X chromosome analysis

110

Previously unanalysed X chromosome data for 41,567 samples (15,146 cases and 26,421 controls totalling 19,576 women and 21,991 men), compiled from two recent ALS GWAS cohorts^{2,22}, were analysed to identify genetic associations between ALS and X-chromosome variants. Only samples passing QC in the base papers with associated X chromosome data were retained. This dataset was analysed separately from the autosomal GWAS datasets due to both the different sample composition (X chromosome data were unavailable for many samples) and different QC and analysis strategies needed to perform robust X chromosome association analysis.

Data from the raw cohorts were mapped to GRCh37 using liftOver and for each cohort we performed an initial pre-

sex; ii) SNPs with minor allele frequencies (MAF) < 0.01 in either sex; iii) SNPs showing significant deviation from

imputation QC. Briefly, we split cohorts by sex, then for each we removed: i) SNPs with missingness > 0.02 in either

Hardy-Weinberg equilibrium (HWE; $p < 1 \times 10^{-4}$); iv) strand ambiguous AT or GC SNPs; v) SNPs showing

heterozygous calls on the X-chromosome in men. Cohorts were then merged into 28 genotyping platform- and

country-matched strata which were balanced for case-control ratio following the scheme of the source papers^{2,22} and

- subject to a second round of QC, removing SNPs per stratum with: i) significant deviation from HWE ($p < 1 \times 10^{-5}$);
- ii) missingness > 0.1; iii) MAF < 0.01. Finally, one sample from any pair with a coefficient of relatedness greater than
 0.125 was removed.
- For imputation, input VCF files aligned to the Haplotype Reference Consortium (HRC) reference allele were prepared
- 119 following the Michigan Imputation Server best practices guidelines. Imputation was then carried out per stratum on

the Michigan imputation server using the HRC (version r1.1 2016) as a reference panel, Eagle 2.4 for phasing and

Minmac 4 for imputation. Following imputation, SNPs with an Rsq value of 0.3 or greater were retained and subjected

to a final round of QC, including removal of SNPs: i) significantly deviating from HWE ($p < 1 \times 10^{-5}$) per stratum; ii)

with missingness > 0.05 in the whole dataset; iii) with MAF < 0.01 in the whole dataset.

For association testing, strata were merged using plink, male genotypes were recoded as 0/1 and the software XWAS²³

125 was run using a sex-stratified model with 20 principal components calculated from autosomal SNPs as covariates.

126 Test statistics for males and females were combined across sexes using Fisher's method (--fisher), which does

not make assumptions about X inactivation, simplifying interpretation.

128 Transcriptomic analyses

We carried out a transcriptome-wide association study (TWAS) using FUSION²⁴ on the summary statistics from the

male and female GWAS for ALS to test for association between gene expression and ALS in 13 brain tissues from

GTEx version 8. For this analysis we used the European subset of the 1000 Genomes Project as an LD reference panel

- and precomputed weights from all GTEx samples (http://gusevlab.org/projects/fusion/). Resulting p-values per gene
- were aggregated across brain tissues using the SCAT method developed by Xiao et al. $(2020)^5$.

To analyse sex-specific TWAS hits in IPSC-derived motor neurones, raw transcriptomic count data for 773 samples 134 were downloaded from the Answer ALS data portal (version 6.0; January 2024). Definite ALS cases and controls 135 were extracted based on clinical metadata, excluding non-ALS MND and asymptomatic carriers. Count data were 136 normalised and converted to counts per million (CPM) using the edgeR package. Association between ALS and gene 137 expression for MEF2C and RESP18 was estimated using a logistic regression model in R and computed in the full 138 dataset (471 ALS, 283 control) as well as male-stratified (294 ALS, 87 control) and female-stratified (177 ALS, 196 139 control) subsets of the data. A Bonferonni adjusted p-value threshold of P<0.0083 was used to correct for multiple 140 testing (6 tests).

141

Heritability enrichment of MEF2C targets 142

Stratified LD score regression⁷ was used to analyse heritability enrichment in a set of genes⁹ differentially expressed 143

after Mef2c conditional knockout in developing mice8. This analysis was run using sex-stratified GWAS summary 144

statistics and combined data from the European-only subset of the 2021 ALS GWAS². An annotation was first made 145

for SNPs in a 100 kb region surrounding each differentially-expressed gene. LD scores were calculated for this 146

annotation using the European subset of the 1000 Genomes Project dataset and considering only HapMap 3 SNPs. 147

The annotation was run against the baseline LD model. 148

References 149

- 1. Ryan, M., Heverin, M., McLaughlin, R. L. & Hardiman, O. Lifetime Risk and Heritability of Amyotrophic Lateral 150 Sclerosis. JAMA Neurol. 76, 1367-1374 (2019). 151
- 2. van Rheenen, W. et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 152 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet. 53, 1636–1648 (2021). 153
- 3. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide 154 association studies. Nat. Genet. 47, 291-295 (2015). 155
- 4. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236-156 1241 (2015). 157
- 5. Xiao, L. et al. Multiple-Tissue Integrative Transcriptome-Wide Association Studies Discovered New Genes 158 Associated With Amyotrophic Lateral Sclerosis. Front. Genet. 11, 587243 (2020). 159
- 6. Baxi, E. G. et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-160 omics data from induced pluripotent cell lines. Nat. Neurosci. 25, 226-237 (2022). 161
- 7. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary 162 statistics. Nat. Genet. 47, 1228-1235 (2015). 163
- 8. Harrington, A. J. et al. MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to 164 neurodevelopmental disorders. eLife 5, e20059 (2016). 165

- P. Cosgrove, D. *et al.* Genes influenced by MEF2C contribute to neurodevelopmental disease via gene expression
 changes that affect multiple types of cortical excitatory neurons. *Hum. Mol. Genet.* **30**, 961–970 (2021).
- 10. Manjaly, Z. R. *et al.* The sex ratio in amyotrophic lateral sclerosis: A population based study. *Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis.* 11, 439–442 (2010).
- 11. Arosio, A. *et al.* MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients. *Mol. Cell. Neurosci.* 74, 10–17 (2016).
- 12. Darlington, D., Schiller, M., Mains, R. & Eipper, B. The expression of regulated endocrine-specific protein of 18
 kDa in peptidergic cells of rat peripheral endocrine tissues and in blood. *J. Endocrinol.* 155, 329–341 (1997).
- 174 13.Su, J. *et al.* RESP18 deficiency has protective effects in dopaminergic neurons in an MPTP mouse model of
 175 Parkinson's disease. *Neurochem. Int.* 118, 195–204 (2018).
- 14.Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat. Genet.* 54, 412–436 (2022).
- 15. Nagle, M. W. *et al.* The 4p16.3 Parkinson Disease Risk Locus Is Associated with GAK Expression and Genes
 Involved with the Synaptic Vesicle Membrane. *PLOS ONE* 11, e0160925 (2016).
- 16.Li, Y. *et al.* Identification of novel genes for age-at-onset of Alzheimer's disease by combining quantitative and
 survival trait analyses. *Alzheimers Dement.* 19, 3148–3157 (2023).
- 17.Camu, W. *et al.* Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A
 phase 2a randomised, double-blind, placebo-controlled trial. *EBioMedicine* 59, 102844 (2020).
- 18. Falconer, D. S. The inheritance of liability to diseases with variable age of onset, with particular reference to
 diabetes mellitus. *Ann. Hum. Genet.* **31**, 1–20 (1967).
- 19.Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic
 association studies. *Nat. Genet.* 50, 1335–1341 (2018).
- 20. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans.
 Bioinforma. Oxf. Engl. 26, 2190–2191 (2010).
- 21.Grotzinger, A. D., Fuente, J. de la, Privé, F., Nivard, M. G. & Tucker-Drob, E. M. Pervasive Downward Bias in
 Estimates of Liability-Scale Heritability in Genome-wide Association Study Meta-analysis: A Simple Solution.
 Biol. Psychiatry 93, 29–36 (2023).
- 22. van Rheenen, W. *et al.* Genome-wide association analyses identify new risk variants and the genetic architecture
 of amyotrophic lateral sclerosis. *Nat. Genet.* 48, 1043–1048 (2016).
- 23.Gao, F. *et al.* XWAS: A Software Toolset for Genetic Data Analysis and Association Studies of the X
 Chromosome. *J. Hered.* 106, 666–671 (2015).

24. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association studies. *Nat. Genet.* 48, 245–
 252 (2016).

Acknowledgements

This study was funded by the MND Association of England, Wales and Northern Ireland under grant number 879-200 791. Data used in the preparation of this article were obtained from the ANSWER ALS Data Portal (AALS-01184). 201 For up-to-date information on the study, visit https://dataportal.answerals.org. This publication has emanated from 202 research supported in part by a research grant from Science Foundation Ireland (SFI) under Grant Number 203 21/RC/10294 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners. 204 R.P.B. currently receives support from the MND Association (979-799). A.I. is funded by South London and 205 Maudsley NHS Foundation Trust, MND Scotland, Motor Neurone Disease Association, National Institute for Health 206 and Care Research, Spastic Paraplegia Foundation, Rosetrees Trust, Darby Rimmer MND Foundation, the Medical 207 Research Council (UKRI), Alzheimer's Research UK and LifeArc. AAK is funded by ALS Association Milton 208 Safenowitz Research Fellowship (grant number22-PDF- 609.DOI:10.52546/pc.gr.150909.), the Motor Neurone 209 Disease Association (MNDA) Fellowship (Al Khleifat/Oct21/975-799), The Darby Rimmer Foundation, and The 210 NIHR Maudsley Biomedical Research Centre. AAC is an NIHR Senior Investigator (NIHR202421). This is an EU 211 Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the 212 following funding organisations under the aegis of JPND - www.jpnd.eu (United Kingdom, Medical Research 213 Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)) and through 214 the Motor Neurone Disease Association, My Name'5 Doddie Foundation, and Alan Davidson Foundation. This study 215 represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical 216 Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. 217

Author contributions

R.L.McL. and R.P.B. conceived the study and drafted the manuscript. R.P.B. conducted the analyses with the assistance of T.D.S, C.M.K. and E.K. W.v.R., A.A-K., A.I., A.A-C. and J.H.V. supplied data for GWAS and XWAS analyses. All authors provided critical review of the manuscript.

Data availability

The GWAS summary statistics generated in this study will be made publicly available upon publication in the NHGRI-223 EBI GWAS Catalog at https://www.ebi.ac.uk/gwas/ (for female, male and X chromosome meta-analyses, 224 respectively) and through the Project MinE website (https://www.projectmine.com/research/download-data/). 225 Individual level genotype data used in this study was originally published in van Rheenen et al 2021 which includes 226 the following publicly available datasets: the Wellcome Trust Case Control Consortium (https://www.wtccc.org.uk/) 227 and dbGaP datasets (phs000101.v3.p1, NIH Genome-Wide Association Studies of Amyotrophic Lateral 228 Sclerosis; phs000126.v1.p1, CIDR: Genome Wide Association Study in Familial Parkinson Disease 229 (PD); phs000196.v1.p1, Genome-Wide Association Study of Parkinson Disease: 230 Genes and Environment; phs000344.v1.p1, Genome-Wide Association Study of Amyotrophic Lateral Sclerosis in 231

Finland; phs000336, a Genome-Wide Association Study of Lung Cancer Risk; phs000346, Genome-Wide 232 Association Study for Bladder Cancer Risk; phs000789, Collaborative Study of Genes, Nutrients and Metabolites 233 (CSGNM); phs000206, Whole Genome Scan for Pancreatic Cancer Risk in the Pancreatic Cancer Cohort Consortium 234 and Pancreatic Cancer Case-Control Consortium (PanScan); phs000297, eMERGE Network Study of the Genetic 235 Determinants of Resistant Hypertension; phs000652, Cohort-Based Genome-Wide Association Study of Glioma 236 (GliomaScan); phs000869, Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study 237 (BEAGESS); phs000812, the Breast and Prostate Cancer Cohort Consortium (BPC3) GWAS of Aggressive Prostate 238 Cancer and ER⁻ Breast Cancer; phs000428, Genetics Resource with the HRS; phs000360.v3, eMERGE Network 239 Genome-Wide Association Study of Red Cell Indices, White Blood Count (WBC) Differential, Diabetic Retinopathy, 240 Height, Serum Lipid Levels, Specifically Total Cholesterol, HDL (High Density Lipoprotein), LDL (Low Density 241 Lipoprotein), and Triglycerides, and Autoimmune Hypothyroidism; phs000893.v1, Genome-Wide Association Study 242 of Endometrial Cancer in the Epidemiology of Endometrial Cancer Consortium (E2C2); phs000168.v2, National 243 Institute on Aging-Late Onset Alzheimer's Disease Family Study: Genome-Wide Association Study for 244 Susceptibility Loci; phs000092.v1, Study of Addiction: Genetics and Environment (SAGE); phs000864.v1, Genomic 245 Predictors of Combat Stress Vulnerability and Resilience; phs000170.v2, a Genome-Wide Association Study on 246 Cataract and HDL in the Personalized Medicine Research Project Cohort; phs000431.v2, IgA Nephropathy GWAS 247 on Individuals of European Ancestry (IGANGWAS2); phs000237.v1, Northwestern NUgene Project: Type 2 248 Diabetes; phs000169.v1, Whole Genome Association Study of Visceral Adiposity in the Health Aging and Body 249 Composition (Health ABC) Study; phs000982.v1, Genetic Analysis of Psoriasis and Psoriatic Arthritis: GWAS of 250 Psoriatic Arthritis; phs000289.v2, National Human Genome Research Institute (NHGRI) GENEVA Genome-Wide 251 Association Study of Venous Thrombosis (GWAS of VTE); phs000634.v1, National Cancer Institute (NCI) Genome 252 Wide Association Study (GWAS) of Lung Cancer in Never Smokers; phs000274.v1, Genome-Wide Association 253 Study of Celiac Disease; phs001172.v1, National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's 254 Disease; phs000389.v1, GEnetics of Nephropathy—an International Effort (GENIE) GWAS of Diabetic Nephropathy 255 in the UK GoKinD and All-Ireland Cohorts; phs000460.v1, Genetics of 24 Hour Urine Composition; phs000138.v2, 256 GWAS for Genetic Determinants of Bone Fragility in European-American Premenopausal Women; phs000394.v1, 257 Autopsy-Confirmed Parkinson Disease GWAS Consortium (APDGC); phs000948.v1, Genetic Discovery and 258 Application in a Clinical Setting: Continuing a Partnership (eMERGE Phase II); phs000630.v1, Exome Chip Study 259 of NIMH Controls; phs000678.v1, a Family-Based Study of Genes and Environment in Young-Onset Breast 260 Cancer; phs000351.v1, National Cancer Institute Genome-Wide Association Study of Renal Cell 261 Carcinoma; phs000314.v1, Genetic Associations in Idiopathic Talipes Equinovarus (Clubfoot)-262 GAIT; phs000147.v3, Cancer Genetic Markers of Susceptibility (CGEMS) Breast Cancer Genome-wide Association 263 Study (GWAS)—Primary Scan: Nurses' Health Study—Additional Cases: Nurses' Health Study 2; phs000882.v1, 264 National Cancer Institute (NCI) Prostate Cancer Genome-Wide Association Study for Uncommon Susceptibility Loci 265 (PEGASUS); phs000238.v1, National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) 266 Consortium Glaucoma Genome-Wide Association Study; phs000397.v1, National Institute on Aging (NIA) Long Life 267 Family Study (LLFS); phs000421.v1, a Genome-Wide Association Study of Fuchs' Endothelial Corneal Dystrophy 268 (FECD); phs000142.v1, a Whole Genome Association Scan for Myopia and Glaucoma Endophenotypes using Twin 269 Studies; phs000303.v1, Genetic Epidemiology of Refractive Error in the KORA (Kooperative Gesundheitsforschung 270 in der Region Augsburg) Study; phs000125.v1, CIDR: Collaborative Study on the Genetics of Alcoholism Case 271

- 272 Control Study; phs001039.v1, International Age-Related Macular Degeneration Genomics Consortium—Exome Chip
- Experiment; phs000187.v1, High Density SNP Association Analysis of Melanoma: Case–Control and Outcomes
- Investigation; <u>phs000101.v5</u>, Genome-Wide Association Study of Amyotrophic Lateral Sclerosis; <u>phs002068.v1.p1</u>,
- 275 Sporadic ALS Australia Systems Genomics Consortium (SALSA-SGC)). Gene expression data used in the preparation
- of this article were obtained from the ANSWER ALS Data Portal (AALS-01184). For up-to-date information on the
- study, visit https://dataportal.answerals.org.

278 Conflict of interest statement

- J.H.V. reports to have sponsored research agreements with Biogen and AstraZeneca. AAK is a consultant for NESTA.
- AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GenieUs, GSK,
- Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, and Wave Pharmaceuticals. All other authors have nothing to declare.

283